Ignite Creation Date:
2025-12-24 @ 10:49 PM
Ignite Modification Date:
2026-01-02 @ 7:26 PM
Study NCT ID:
NCT03801369
Status:
TERMINATED
Last Update Posted:
2025-11-21
First Post:
2019-01-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer
Sponsor:
Gordon Mills, MD, PhD
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-12-12
Start Date Type:
ACTUAL
Primary Completion Date:
2024-10-22
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-12-23
Completion Date Type:
ACTUAL
First Submit Date:
2019-01-09
First Submit QC Date:
None
Study First Post Date:
2019-01-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-10-22
Results First Submit QC Date:
None
Results First Post Date:
2025-11-21
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-07
Last Update Post Date:
2025-11-21
Last Update Post Date Type:
ESTIMATED